AutoGenomics specializes in developing automated technologies aimed at enhancing the efficiency and accuracy of genetic analysis in clinical laboratories. Their flagship product, the INFINITI® system, is specifically engineered to process proprietary BioFilmChip® microarrays. These microarrays can be multiplexed to analyze hundreds of biomarkers from a single sample, allowing for comprehensive disease signature assessments. This integration of advanced technology not only streamlines laboratory workflows but also significantly reduces the cost per reportable result, thereby improving overall productivity in clinical settings.

The company’s commitment to advancing healthcare is reflected in its focus on delivering actionable insights through its tests and analytics. By leveraging expertise in various scientific fields, including pharmacology and toxicology, AutoGenomics provides tools that enable healthcare professionals to make informed decisions regarding patient care. This capability allows physicians to prescribe therapies that are more compatible with individual patient profiles and to anticipate potential reactions to treatments, ultimately enhancing the effectiveness of medical interventions.

United States

AutoGenomics is a biotechnology company that offers an automated microarray based multiplexing molecular diagnostic platform to assess disease signatures with novel genetic biomarkers in the areas of women’s health, cancer and personalized medicine.

AutoGenomics

Company Details